Choosing a cell dissociation reagent is a data question: what happens to viability, yield, growth kinetics and phenotype after repeated rounds of detachment — not just in one passage, but across the weeks a real culture runs. Kerry (formerly c-LEcta) has now released exactly that dataset for CellTrypase®, its recombinant trypsin-like enzyme: five consecutive passages in four biopharma production cell lines, and dissociation of human induced pluripotent stem cells (iPSCs) in 2D and 3D formats, all benchmarked against the current industry-standard trypsin-like enzyme. This article summarizes the released figures, states plainly where the data end, and explains how to use a free sample to close the gap for your own cells.
What the released dataset covers — and what it does not
The data come from three manufacturer documents: the scientific poster Advancing cell dissociation in bioprocessing with CellTrypase (Kerry, Feb 2026), the Product Information Sheet v4.0 (Aug 2026), and the Application Note v1.1 (Jun 2026). The test system: cells were dissociated with either 1× CellTrypase or an equivalent amount of the current industry-standard trypsin-like enzyme (the control — the comparator is not named in the source documents), with n = 3 technical replicates and predefined acceptance criteria. Covered: CHO-K1, HEK 293, MDCK, Vero (five passages each) and human iPSCs in 2D colonies, 3D pluripotent aggregates and differentiated 3D aggregates. Not covered by any published figure: hESCs, primary cells, organoids, MSCs and every other cell type — the manufacturer lists these as intended applications, but there is no released performance data for them.
Five-passage performance in production cell lines
A cell dissociation reagent that damages cells shows it over passages: viability drifts down, yields fall, doubling times stretch. Kerry's five-passage study (P0–P4) found none of these signatures. Mean viability with CellTrypase was 95–99% depending on cell line, mean yield was 100–106% of the control, and population doubling times were equal to or slightly shorter than the control in every line.
| Cell line | Dissociation time (control → CellTrypase) | Mean viability | Mean yield (% of control) | Doubling time (control → CellTrypase) |
|---|---|---|---|---|
| CHO-K1 | 02:30 → 02:25 | 98% | 106% | 15:17 → 14:47 h |
| HEK 293 | 02:46 → 02:27 | 95% | 100% | 27:10 → 26:55 h |
| MDCK | 25:23 → 23:32 | 99% | 102% | 19:09 → 18:52 h |
| Vero | 03:59 → 04:07 | 99% | 103% | 19:45 → 19:16 h |
Two honest observations belong next to that table. MDCK, a tightly adherent epithelial line, takes over 20 minutes to release with either enzyme — CellTrypase is faster (23:32 vs 25:23) but not fast. And Vero is the one line where CellTrypase detached slightly slower than the control (4:07 vs 3:59), with equal viability and higher yield. A reagent evaluation that hides numbers like these is not an evaluation.
Test it on your own cells: a free 100 mL sample of CellTrypase (R&D or GMP grade) is available for qualification and process-development testing — the data above cover four cell lines and iPSCs, and your cells are the fifth experiment.
iPSC dissociation in 2D and 3D culture
iPSCs are the stress test for any dissociation enzyme: they are sensitive to proteolysis, prone to aggregate, and must come out of the process still pluripotent. In 2D colonies (Essential 8™ medium), 1× CellTrypase reached single-cell suspension in 5 minutes versus 7 minutes for the control, at 94% viability for both enzymes, 99% relative yield and residual aggregates below 5%. Flow cytometry after dissociation showed the full pluripotency panel — Oct3/4, SSEA4, TRA-1-60, CD30, Nanog, Sox2 and SSEA3 — above the predefined 75% acceptance threshold. Re-seeded cells showed typical colony morphology and reached ≥80% confluency within four days.
In 3D pluripotent aggregates from bioreactor culture, both enzymes needed about 10 minutes; CellTrypase gave 87% viability (control 85%), 104% relative yield and fewer residual aggregates (12% vs 16%). Data on differentiated 3D aggregates — the densest, most adhesion-rich format tested — are in the Application Note v1.1, which the manufacturer supplies on request via our CellTrypase technical documents page.
| iPSC format | Dissociation time (control → CellTrypase) | Viability | Yield (% of control) | Residual aggregates |
|---|---|---|---|---|
| 2D colonies | 7 min → 5 min | 94% (both) | 99% | <5% (both) |
| 3D pluripotent aggregates | 10 min → 10 min | 85% → 87% | 104% | 16% → 12% |
Purity: why a single HPLC peak matters
CellTrypase is released at ≥95% purity by size-exclusion HPLC on every lot — a release specification, not a typical value. The chromatogram of the 10× GMP-grade stock shows a single, well-defined peak; the industry-standard comparator shows a broader peak base with small additional signals that may reflect impurities, inactive enzyme fragments or proteolytic by-products. For a protease applied directly to living cells, off-target proteolytic activity is the mechanism by which a dissociation reagent damages surface markers — published work on other enzymes shows exactly this class of effect (see Tsuji et al., Cell Transplant 2017 on trypsin-sensitive surface antigens, and Lai et al., Sci Rep 2022 on enzyme-cleaved Fas ligand). A cleaner enzyme preparation narrows that risk surface.
Stability update: 21 months at 2–8 °C
The Product Information Sheet v4.0 (August 2026) extends the confirmed shelf life from 15 to at least 21 months from the date of manufacture at 2–8 °C, for both the GMP and R&D grades, based on accumulating real-time stability data. Transport stress testing supports ambient-temperature shipping — temporary room-temperature exposure does not measurably affect activity — so no cold chain is required in transit. Extended storage at or near 37 °C should still be avoided: like any active serine protease, the enzyme slowly digests itself at its activity optimum.
How to evaluate a cell dissociation reagent on your own cells
Manufacturer data narrow the field; they never replace your own qualification. Kerry's study design is itself a reasonable template for an in-lab evaluation:
- Run at least three consecutive passages, not one — single-passage tests miss cumulative effects on growth kinetics.
- Record dissociation time to a defined endpoint (e.g. single-cell suspension confirmed by microscopy), not to a fixed clock time.
- Track viability, yield relative to your current reagent, and doubling time with predefined acceptance criteria (Kerry used ≥85% of control).
- For stem cells, add a phenotype readout — a pluripotency marker panel by flow cytometry, with a threshold set before the experiment.
- Keep the protocol otherwise unchanged: CellTrypase quenches by dilution in medium with no trypsin inhibitor, so a side-by-side against your current enzyme needs no workflow redesign.
For background on how the major reagent classes differ mechanistically, see our TrypLE vs trypsin vs Accutase guide. The full CellTrypase documentation set — PIS v4.0, the four v4.0 product specifications and the scientific poster, plus the request form for the Validation Guide v1.2 and Application Note v1.1 — is on the technical documents page, and the enzyme itself is on the CellTrypase product page alongside the rest of the Kerry (formerly c-LEcta) portfolio.
Sources and disclosures
Performance figures are from Kerry (formerly c-LEcta) documentation: scientific poster #11462 "Advancing cell dissociation in bioprocessing with CellTrypase" (Feb 2026); CellTrypase Product Information Sheet v4.0 (valid as of 18 Aug 2026); CellTrypase Application Note v1.1 (Jun 2026, available on request). The comparator in all studies is described by the manufacturer only as the "current industry standard trypsin-like enzyme" and is not named. Peer-reviewed citations were retrieved from their publishers via DOI. CellTrypase® is a trademark of Kerry Group. TrypLE™ is a trademark of Thermo Fisher Scientific Inc.; Accutase® is a trademark of its respective owner. Neither Thermo Fisher Scientific nor any other third party is affiliated with or endorses BioHippo. For Research Use Only; GMP-grade material is intended as a processing aid in biopharmaceutical manufacturing and is not for direct administration to humans or animals. BioHippo is the authorized United States distributor for the Kerry (formerly c-LEcta) enzyme portfolio.
